Are Shares of OrganiGram (OGI) a Buy, After Their Weak Fourth Quarter?

The recent round of earnings for the vast majority of large-cap cannabis companies in Canada has been weak. Therefore, it wasn’t too much of a surprise when OrganiGram (OGI) reported weaker than expected fourth-quarter on Monday…

OrganiGram posted 2019 revenues of $80.4 million which was a 547% increase year over year from revenues of just $12.4 million back in 2018. Gross margins improved by 2% on a strictly percentage basis growing from 45% to 47%. In 2019 gross margins grew 575% to $37.9 million or 47% of net revenue compared to $5.6 million or 45% of net revenue in 2018. The company also ended the year profitable with 2019 adjusted EBITDA of $19.9 million or 25% of net revenue which was negative $1.0 million just a year ago in 2018.

OrganiGram sells cannabis in all 10 provinces and estimates that they have approximately 10% of the Canadian adult-use recreational market under their belt.

OrganiGram expects to have a much more successful 2020 but what were some of the issues that caused a weak fourth quarter? Canada has been very slow at allowing the rollout of retail stores (to distribute their products) across the country. This has created a…

Continue reading at STOCKNEWS.com

 

You May Also Like

About the Author: admin

Leave a Reply

Your email address will not be published.